Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...